Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
Anna-Maria Lazaratos(McGill University), Matthew Dankner(McGill University), Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier), Nika Dobnikar(Institute of Oncology Ljubljana), Andrew D. Seidman(Memorial Sloan Kettering Cancer Center), Kevin Petrecca(McGill University Health Centre), Nathaniel Bouganim(McGill University Health Centre), Andrea Quaiattini(McGill University), Valentina Guarneri(Istituto Oncologico Veneto), Aki Morikawa(Memorial Sloan Kettering Cancer Center), William Jacot(Inserm), Emanuela Ferraro(University of Milan), April A. N. Rose(Jewish General Hospital), François Panet(McGill University), Zubin Lahijanian(McGill University), Sarah M. Maritan(McGill University), Ivica Ratoša(University of Ljubljana), Alessia Pellerino(University of Turin), Gaia Griguolo(University of North Carolina at Chapel Hill), Riccardo Soffietti(Azienda Ospedaliero Universitaria San Giovanni Battista), Lawrence Panasci(Jewish General Hospital), Hans‐Joachim Stemmler(Ludwig-Maximilians-Universität München), Marcel P. H. van den Broek(St. Antonius Ziekenhuis), Silvia Höfer(University Hospital of Zurich)
Cited by 25
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k